Sirtex wins $1.3m Start grant

By Melissa Trudinger
Thursday, 28 October, 2004

Sirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.

Targeted Hyperthermia Therapy uses the company's microsphere platform technology to deliver magnetic nanoparticles to tumours, followed by treatment with an alternating magnetic field to heat up the tumour causing death of the cancer cells.

The company has recently overcome some technical issues regarding the scale up of the treatment from animals to humans.

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Content from other channels on our network

Industry transitions from gas to renewable heat: report

Boral launches detailed carbon reporting capability

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award

Industrial electricity costs could halve by sharing infrastructure

The roles of the vendor and EPCs in the project bidding process

Seeq and Applied Computing partner on industrial AI for energy operations

ARENA opens Round 3 of Solar Sunshot with $250m available

Testing Profinet I/O devices without a dedicated PLC

CCEP's $39.7m can line upgrade in Perth increases capacity 40%

Beverage facility built to keep the good times rolling

Industries transitioning away from gas, A2EP report released

Six on the shelf: from frozen treats to smoothies & meal kits

58% of food manufacturers report less productivity, research finds

Leadership change at CCEP Australia next year